- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Therapeutic Areas
- Oncology
- Publications
- Programs
- Pipeline
- mTORC1/2 inhibitor Sapanisertib
- SYK Inhibitor Mivavotinib
- Preclinical Programs
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Clinical Trials
Clinical Trials Overview
Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, we are advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.
Clinical Trials
Indication Program Study Information Diffuse Large B-Cell Lymphoma Mivavotinib Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Squamous non-Small Cell Lung Cancer Sapanisertib A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Indication Diffuse Large B-Cell Lymphoma Program Mivavotinib Study Info Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Indication Squamous non-Small Cell Lung Cancer Program Sapanisertib Study Info A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Expanded Access Policy
We are committed to eligible patients
gaining access to our clinical trials.